Personalized therapy reduces cancer risk for diabetics
It has long been known that type 2 diabetes has an increased risk of cancer. There are also indications that certain diabetes medications can increase the risk of developing cancer. However, Austrian scientists have now been able to show that such risks can be eliminated by personalized therapy.
Complex relationships between diabetes and cancer
The relationships between type 2 diabetes and cancer are complex. On the one hand, people who have diabetes mellitus generally have an increased risk of developing cancer. For example, US researchers recently reported that obesity and type 2 diabetes increase the risk of liver cancer. On the other hand, some diabetes medications are suspected of increasing the risk of bladder cancer, for example.
Common risk factors
However, scientists at MedUni Vienna have now been able to show that these risks can now be practically eliminated with optimized, personalized therapy.
Alexandra Kautzky-Willer, gender medicine and diabetes expert at MedUni Vienna, said in a statement from the university: “Cancer and diabetes have common risk factors such as obesity, smoking, eating habits, lack of exercise, insulin resistance, inflammatory and hormonal changes and can also be bad stopped diabetes with high blood sugar increases the risk of cancer. "
Eliminate risk through targeted measures in precision medicine
The study by the Austrian researchers shows that targeted measures in precision medicine can eliminate the risk.
And also that simultaneous treatment with statins (which are mainly used to lower cholesterol in fat metabolism disorders) is even associated with a reduced risk of cancer.
For the study, which was published in the journal "Journal of Internal Medicine", 1.85 million Austrians who were hospitalized at least once were recorded statistically. Around 300,000 of these had type 2 diabetes. The patients were treated with around 300 different combinations of diabetes medications.
Some drugs increase the risk of cancer
The study found that primary insulin-increasing drugs (sulfonylurea and insulin) showed a significantly increased risk of cancer compared to insulin-inhibiting drugs, especially for pancreatic cancer (pancreas) in men and women, as well as liver cancer in men and lymphoma cancer in women .
"However, if statins are taken at the same time, this risk is reduced massively and towards zero compared to patients without diabetes," says Kautzky-Willer.
Individual therapy for patients
Peter Klimek from the Institute for Science of Complex Systems added: “This shows that individual therapy can be optimized in such a way that the general cancer risk for diabetes patients can be significantly reduced. In precision medicine today we have a large selection of medications and possible combination therapies that make this possible. ”
Earlier studies have shown that personalized therapies are for the benefit of the patient. For example, the pancreas center of the University Clinic Düsseldorf (UKD) reported last year that individual treatment improves the chances of recovery from pancreatic cancer. (ad)